表 7.
阿替利珠单抗联合吉西他滨和顺铂组的不良事件(≥10%)
Adverse events in the atezolizumab plus gemcitabine and cisplatin arm(≥10%)
| Items | Atezolizumab+ gemcitabine+ cisplatina (n=20) |
| a, percentages are based on n in the column heading. For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once. | |
| Anemia | 15 (75.0) |
| Decreased appetite | 13 (65.0) |
| White blood cell count decreased | 13 (65.0) |
| Nausea | 11 (55.0) |
| Platelet count decreased | 11 (55.0) |
| Neutrophil count decreased | 10 (50.0) |
| Neutropenia | 8 (40.0) |
| Vomiting | 8 (40.0) |
| Alanine aminotransferase increased | 7 (35.0) |
| Hypoalbuminemia | 6 (30.0) |
| Leukopenia | 6 (30.0) |
| Thrombocytopenia | 6 (30.0) |
| Fatigue | 5 (25.0) |
| Pyrexia | 5 (25.0) |
| Rash | 5 (25.0) |
| Aspartate aminotransferase increased | 4 (20.0) |
| Asthenia | 4 (20.0) |
| Hyponatremia | 4 (20.0) |
| Lymphocyte count decreased | 4 (20.0) |
| Productive cough | 4 (20.0) |
| Blood lactate dehydrogenase increased | 3 (15.0) |
| Bone marrow failure | 3 (15.0) |
| Chest pain | 3 (15.0) |
| Constipation | 3 (15.0) |
| Gamma-glutamyltransferase increased | 3 (15.0) |
| Hemoptysis | 3 (15.0) |
| Hypoproteinemia | 3 (15.0) |
| Weight decreased | 3 (15.0) |
| Abdominal discomfort | 2 (10.0) |
| Amylase increased | 2 (10.0) |
| Bilirubin conjugated increased | 2 (10.0) |
| Blood bilirubin increased | 2 (10.0) |
| Blood creatinine increased | 2 (10.0) |
| Hypochloremia | 2 (10.0) |
| Hypokalemia | 2 (10.0) |
| Hypothyroidism | 2 (10.0) |